Express News | Hongri Pharmaceutical: Obtained Valsartan Amlodipine Tablets (I) Drug Registration Certificate

BreakingsApr 24 16:33

Joint Credit: Follow the changes in the chairman and general manager of Hongri Pharmaceutical

Joint Financial Credit is concerned that according to the “Notice Concerning the Resignation of the Chairman of the Company and By-election of the Director, Chairman, Vice Chairman, and Adjustment of Special Committee Members and the Appointment of the Company's Senior Management” disclosed by Hongri Pharmaceutical on April 2, 2024, and the “Notice Concerning the Retirement and Resignation of the Company's Vice Chairman, Director and General Manager” disclosed on March 12, 2024, Mr. Yao Xiaoqing applied to resign as the company's legal representative, chairman, director and relevant positions in the special committee of the board of directors after resigning; former vice chairman, Ms. Zheng Dan, director and general manager, is

Zhitong FinanceApr 8 19:48

Red Sun Pharmaceutical (300026.SZ): Yao Xiaoqing resigns as chairman

Gelonghui, April 1, 丨 Hongri Pharmaceutical (300026.SZ) announced that the board of directors of the company recently received a written application for resignation from Mr. Yao Xiaoqing, the chairman of the company. Mr. Yao Xiaoqing applied to resign as the company's legal representative, chairman, director and relevant positions in the special committee of the board of directors due to personal work reasons. After his resignation, he no longer held any position in the company.

Gelonghui FinanceApr 1 17:01

Hongri Pharmaceutical (300026.SZ): The subsidiary looks forward to the pharmaceutical industry selling esprolol hydrochloride raw materials

Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform. “Do your company and subsidiaries have esprolol hydrochloride APIs and corresponding formulations?” The company replied that the company's subsidiary expects the pharmaceutical industry to sell esprolol hydrochloride APIs.

Gelonghui FinanceMar 29 16:23

Hongri Pharmaceutical (300026.SZ): Ketorolac tromethanol injection is currently under CDE review

Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform, “The consistency evaluation of your company's ketorolac tromethotriol injection completed various technical reviews at the end of August 2023. Why hasn't it been approved until now?” The company replied that ketorolac and tromethotriol injections are currently under CDE review.

Gelonghui FinanceMar 29 16:16

Red Sun Pharmaceutical (300026.SZ): Net profit for 2023 will drop 18.84% to 507 million yuan, and plans to distribute 10 to 0.3 yuan

Gelonghui March 28 | Hongri Pharmaceutical (300026.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 6.109 billion yuan, a year-on-year decrease of 8.14%; net profit attributable to shareholders of listed companies was 507 million yuan. , a year-on-year decrease of 18.84%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376 million yuan, a year-on-year decrease of 34.20%; basic earnings per share were 0.17 yuan; it is proposed to distribute a cash dividend of 0.30 yuan (tax included) for every 10 shares to all shareholders.

Gelonghui FinanceMar 28 21:30